Skip to main content

Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment


Pancreatic cancer has been termed a ‘recalcitrant cancer’ due to its relative resistance to chemotherapy and immunotherapy. This resistance is thought to be due in part to the dense fibrotic tumor microenvironment and lack of tumor infiltrating CD8 + T cells. The gastrointestinal peptide, gastrin, has been shown to stimulate growth of pancreatic cancer by both a paracrine and autocrine mechanism. Interruption of gastrin at the CCK receptor may reduce tumor-associated fibrosis and alter tumor immune cells. Polyclonal Ab Stimulator (PAS) is a vaccine that targets gastrin and has been shown to prolong survival of patients with pancreatic cancer. Here, we report that PAS vaccination monotherapy elicits both a humoral and cellular immune response when used in immune competent mice-bearing pancreatic tumors and that PAS monotherapy produced a marked T-cell activation and influx of CD8 + lymphocytes into pancreatic tumors. Isolated peripheral lymphocytes elicited cytokine release upon re-stimulation with gastrin in vitro demonstrating specificity of immune activation for the target peptide. Combination therapy with PAS and PD-1 Ab activated CD4 −/CD8 − TEMRA cells important in T-cell-mediated tumor death and memory. Tumors of mice treated with PAS (250 μg) or PAS (100 and 250 μg) in combination with a PD-1 Ab were significantly smaller compared to tumors from PBS or PD-1 Ab-treated mice. When PAS was given in combination with PD-1 Ab, tumors had less fibrosis, fewer inhibitory Treg lymphocytes, and fewer tumor-associated macrophages. These findings reveal a novel approach to improve treatment strategies for pancreatic cancer.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6













Polyclonal antibody stimulator


100 µg Polyclonal antibody stimulator


250 µg Polyclonal antibody stimulator


Pancreatic ductal adenocarcinoma




Tumor-associated macrophages


Terminally differentiated T cells


Tumor microenvironment


  1. 1.

    Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362:1605–1617

    CAS  Google Scholar 

  2. 2.

    Ryan DP, Hong TS, Bardeesy N (2014) Pancreatic adenocarcinoma. N Engl J Med 371:1039–1049

    CAS  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Falconi M, Mantovani W, Bettini R, Talamini G, Bassi C, Cascinu S, Oliani C, Pederzoli P (2003) Carcinoma of pancreatic body and tail: are there improvements in diagnosis and treatment modalities over the past decade? Dig Liver Dis 35:421–427

    CAS  PubMed  Google Scholar 

  4. 4.

    Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30

    Google Scholar 

  5. 5.

    Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM, Tuveson DA (2011) Stromal biology and therapy in pancreatic cancer. Gut 60:861–868

    PubMed  Google Scholar 

  6. 6.

    Templeton AW, Brentnall TA (2013) Screening and surgical outcomes of familial pancreatic cancer. Surg Clin N Am 93:629–645

    PubMed  Google Scholar 

  7. 7.

    Zheng L, Xue J, Jaffee EM, Habtezion A (2013) Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology 144:1230–1240

    PubMed  PubMed Central  Google Scholar 

  8. 8.

    Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA (2012) The pancreas cancer microenvironment. Clin Cancer Res 18:4266–4276

    CAS  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Quante M, Varga J, Wang TC, Greten FR (2013) The gastrointestinal tumor microenvironment. Gastroenterology 145:63–78

    PubMed  PubMed Central  Google Scholar 

  10. 10.

    Vonderheide RH, Bayne LJ (2013) Inflammatory networks and immune surveillance of pancreatic carcinoma. Curr Opin Immunol 25:200–205

    CAS  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 Ab in patients with advanced cancer. N Engl J Med 366:2455–2465

    CAS  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264

    CAS  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS (2014) Predictive correlates of response to the anti-PD-L1 Ab MPDL3280A in cancer patients. Nature 515:563–567

    CAS  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Hilmi M, Bartholin L, Neuzillet C (2018) Immune therapies in pancreatic ductal adenocarcinoma: where are we now? World J Gastroenterol 24:2137–2151

    CAS  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, Drengler R, Chen C, Smith L, Espino G, Gergich K, Delgado L, Daud A, Lindia JA, Li XN, Pierce RH, Yearley JH, Wu D, Laterza O, Lehnert M, Iannone R, Tolcher AW (2015) Phase I study of pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Ab) in patients with advanced solid tumors. Clin Cancer Res 21:4286–4293

    CAS  Google Scholar 

  16. 16.

    Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, Rosenberg SA (2010) Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 33:828–833

    CAS  PubMed  Google Scholar 

  17. 17.

    Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA, Yano M, Fowler KJ, Lockhart AC, Suresh R, Tan BR, Lim KH, Fields RC, Strasberg SM, Hawkins WG, Denardo DG, Goedegebuure SP, Linehan DC (2016) Targeting tumour-associated macrophages with CCR17 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol 17:651–662

    CAS  PubMed  PubMed Central  Google Scholar 

  18. 18.

    Schally AV, Nagy A (2004) Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab 15:300–310

    CAS  PubMed  Google Scholar 

  19. 19.

    Smith JP, Fantaskey AP, Liu G, Zagon IS (1995) Identification of gastrin as a growth peptide in human pancreatic cancer. Am J Physiol 268:R135–R141

    CAS  PubMed  Google Scholar 

  20. 20.

    Smith JP, Shih A, Wu Y, McLaughlin PJ, Zagon IS (1996) Gastrin regulates growth of human pancreatic cancer in a tonic and autocrine fashion. Am J Physiol 270:R1078–R1084

    CAS  PubMed  Google Scholar 

  21. 21.

    Matters GL, Harms JF, McGovern CO, Jayakumar C, Crepin K, Smith ZP, Nelson MC, Stock H, Fenn CW, Kaiser J, Kester M, Smith JP (2009) Growth of human pancreatic cancer is inhibited by down-regulation of gastrin gene expression. Pancreas 38:e151–e161

    CAS  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Smith JP, Liu G, Soundararajan V, McLaughlin PJ, Zagon IS (1994) Identification and characterization of CCK-B/gastrin receptors in human pancreatic cancer cell lines. Am J Physiol 266:R277–R283

    CAS  PubMed  Google Scholar 

  23. 23.

    Smith JP, Solomon TE (2014) Cholecystokinin and pancreatic cancer: the chicken or the egg? Am J Physiol Gastrointest Liver Physiol 306:G91–G101

    PubMed  Google Scholar 

  24. 24.

    Zhang JG, Liu JX, Jia XX, Geng J, Yu F, Cong B (2014) Cholecystokinin octapeptide regulates the differentiation and effector cytokine production of CD4 T cells in vitro. Int Immunopharmacol 20:307–315

    CAS  PubMed  Google Scholar 

  25. 25.

    Berna MJ, Seiz O, Nast JF, Benten D, Blaker M, Koch J, Lohse AW, Pace A (2010) CCK1 and CCK2 receptors are expressed on pancreatic stellate cells and induce collagen production. J Biol Chem 285:38905–38914

    CAS  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Singh P, Owlia A, Espeijo R, Dai B (1995) Novel gastrin receptors mediate mitogenic effects of gastrin and processing intermediates of gastrin on Swiss 3T3 fibroblasts. Absence of detectable cholecystokinin (CCK)-A and CCK-B receptors. J Biol Chem 270:8429–8438

    CAS  PubMed  Google Scholar 

  27. 27.

    Smith JP, Cooper TK, McGovern CO, Gilius EL, Zhong Q, Liao J, Molinolo AA, Gutkind JS, Matters GL (2014) Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice. Pancreas 43:1050–1059

    CAS  PubMed  PubMed Central  Google Scholar 

  28. 28.

    Smith JP, Wang S, Nadella S, Jablonski SA, Weiner LM (2018) Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint Ab therapy in mice. Cancer Immunol Immunother 67:195–207

    CAS  PubMed  Google Scholar 

  29. 29.

    Watson SA, Michaeli D, Grimes S, Morris TM, Robinson G, Varro A, Justin TA, Hardcastle JD (1996) Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer. Cancer Res 56:880–885

    CAS  PubMed  Google Scholar 

  30. 30.

    Watson SA, Morris TM, Varro A, Michaeli D, Smith AM (1999) A comparison of the therapeutic effectiveness of gastrin neutralisation in two human gastric cancer models: relation to endocrine and autocrine/paracrine gastrin mediated growth. Gut 45:812–817

    CAS  PubMed  PubMed Central  Google Scholar 

  31. 31.

    Brett BT, Smith SC, Bouvier CV, Michaeli D, Hochhauser D, Davidson BR, Kurzawinski TR, Watkinson AF, Van SN, Pounder RE, Caplin ME (2002) Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J Clin Oncol 20:4225–4231

    CAS  PubMed  Google Scholar 

  32. 32.

    Gilliam AD, Broome P, Topuzov EG, Garin AM, Pulay I, Humphreys J, Whitehead A, Takhar A, Rowlands BJ, Beckingham IJ (2012) An international multicenter randomized controlled trial of G17DT in patients with pancreatic cancer. Pancreas 41:374–379

    CAS  PubMed  Google Scholar 

  33. 33.

    Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, Jager M, Ponz-Sarvise M, Tiriac H, Spector MS, Gracanin A, Oni T, Yu KH, van Boxtel R, Huch M, Rivera KD, Wilson JP, Feigin ME, Ohlund D, Handly-Santana A, Ardito-Abraham CM, Ludwig M, Elyada E, Alagesan B, Biffi G, Yordanov GN, Delcuze B, Creighton B, Wright K, Park Y, Morsink FH, Molenaar IQ, Borel Rinkes IH, Cuppen E, Hao Y, Jin Y, Nijman IJ, Iacobuzio-Donahue C, Leach SD, Pappin DJ, Hammell M, Klimstra DS, Basturk O, Hruban RH, Offerhaus GJ, Vries RG, Clevers H, Tuveson DA (2015) Organoid models of human and mouse ductal pancreatic cancer. Cell 160:324–338

    CAS  Google Scholar 

  34. 34.

    Smith JP, Wang S, Nadella S, Jablonski SA, Weiner LM (2018) Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint Ab therapy in mice. Cancer Immunol Immunother 67:195–207

    CAS  PubMed  Google Scholar 

  35. 35.

    Kiyotani K, Chan HT, Nakamura Y (2018) Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens. Cancer Sci 109:542–549

    CAS  PubMed  PubMed Central  Google Scholar 

  36. 36.

    Nizard M, Roussel H, Diniz MO, Karaki S, Tran T, Voron T, Dransart E, Sandoval F, Riquet M, Rance B, Marcheteau E, Fabre E, Mandavit M, Terme M, Blanc C, Escudie JB, Gibault L, Barthes FLP, Granier C, Ferreira LCS, Badoual C, Johannes L, Tartour E (2017) Induction of resident memory T cells enhances the efficacy of cancer vaccine. Nat Commun 8:15221

    CAS  PubMed  PubMed Central  Google Scholar 

  37. 37.

    Willcox BE, Willcox CR (2019) gammadelta TCR ligands: the quest to solve a 500-million-year-old mystery. Nat Immunol 20:121–128

    CAS  PubMed  Google Scholar 

  38. 38.

    Zhao Y, Niu C, Cui J (2018) Gamma-delta (gammadelta) T cells: friend or foe in cancer development? J Transl Med 16:3

    CAS  PubMed  PubMed Central  Google Scholar 

  39. 39.

    Janakiram NB, Mohammed A, Bryant T, Ritchie R, Stratton N, Jackson L, Lightfoot S, Benbrook DM, Asch AS, Lang ML, Rao CV (2017) Loss of natural killer T cells promotes pancreatic cancer in LSL-Kras(G12D/+) mice. Immunology 152:36–51

    CAS  PubMed  PubMed Central  Google Scholar 

  40. 40.

    He QF, Xu Y, Li J, Huang ZM, Li XH, Wang X (2019) CD8 + T-cell exhaustion in cancer: mechanisms and new area for cancer immunotherapy. Brief Funct Genom 18:99–106

    Google Scholar 

  41. 41.

    Lohneis P, Sinn M, Bischoff S, Juhling A, Pelzer U, Wislocka L, Bahra M, Sinn BV, Denkert C, Oettle H, Blaker H, Riess H, Johrens K, Striefler JK (2017) Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. Eur J Cancer 83:290–301

    CAS  PubMed  Google Scholar 

  42. 42.

    Zhang Z, Zhang C, Li F, Zhang B, Zhang Y (2018) Regulation of memory CD8 + T cell differentiation by MicroRNAs. Cell Physiol Biochem 47:2187–2198

    CAS  PubMed  Google Scholar 

  43. 43.

    Abu Eid R, Razavi G, Mkrtichyan M, Janik J, Khleif SN (2016) Old-school chemotherapy in immunotherapeutic combination in cancer, a low-cost drug repurposed. Cancer Immunol Res 4:377–382

    CAS  PubMed  Google Scholar 

  44. 44.

    Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, Onners B, Uram JN, Laheru DA, Lutz ER, Solt S, Murphy AL, Skoble J, Lemmens E, Grous J, Dubensky T Jr, Brockstedt DG, Jaffee EM (2015) Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cance. J Clin Oncol 33:1325–1333

    CAS  PubMed  PubMed Central  Google Scholar 

  45. 45.

    Mkrtichyan M, Najjar YG, Raulfs EC, Abdalla MY, Samara R, Rotem-Yehudar R, Cook L, Khleif SN (2011) Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur J Immunol 41:2977–2986

    CAS  PubMed  Google Scholar 

Download references


We appreciate the technical support from the staff in the Lombardi Georgetown Comprehensive Cancer Center Core Histology laboratory and Flow cytometry facilities. We also appreciate the staff in the animal care facility. All the investigations in this project were done at Georgetown University School of Medicine in the research laboratory of Dr. Smith, comparative medicine animal facility, and core labs (above) in the Lombardi Georgetown Comprehensive Cancer Center.


The study was funded in part by a grant from Cancer Advances, Inc. and its subsidiary Vaccicure, and NIH CA051008 to the Georgetown Lombardi Cancer center Core facilities.

Author information




JPS, NO, RS, LS and AC conceived and designed research; JPS, JB, HC, and XL performed experiments; JPS, NO, RS, JB, HC, XL, AHK, LS and AC analyzed data; JPS, NO, RS, JB, HC, AHK, LS, and AC interpreted results of experiments; JPS, XL, and HC prepared figures; JPS drafted manuscript; NO, RS, JB, HC, XL, AHK, LS, AC, and JPS edited and revised manuscript; ALL authors approved the content of the final version of manuscript.

Corresponding author

Correspondence to Jill P. Smith.

Ethics declarations

Conflict of interest

Cato Research, Durham NC has intellectual property rights for PAS. PAS compound was transferred to Georgetown University by a Material Transfer agreement with Vaccicure Limited, Liverpool, UK for this research project. All authors work for Cato Research or Georgetown University.

Ethical approval and ethical standards

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the Georgetown University. The IACUC Protocol Number was 2016-1193 and the protocol approval date was 10/05/2017.

Animal source

C57BL/6 mice were purchased from Charles River Laboratories (Maryland).

Cell line authentication

Murine pancreatic cancer cells, mT3, were a gift from the Tuveson lab (Cold Spring Harbor, NY). Authentication of mT3 murine cells was performed by the investigator that developed the cells [33] and further IMPACT-III testing was performed by IDEXX BioResearch (Columbia, MO) to ensure the cells were pathogen-free.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 614 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Osborne, N., Sundseth, R., Burks, J. et al. Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment. Cancer Immunol Immunother 68, 1635–1648 (2019).

Download citation


  • Tumor microenvironment
  • Vaccine
  • Gamma–delta T cells
  • NKT cells
  • Cellular immunity
  • Gastrin